Nkarta (NKTX) Stock Price, News & Analysis

Company Overview

Nkarta, Inc. is a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies for the treatment of cancer. The company’s approach is designed to use allogeneic, or donor-derived, immune cells that can be manufactured for use across multiple patients, with the goal of providing an off-the-shelf alternative to individualized cell therapies.

Nkarta’s product candidates include NKX101, an engineered CAR NK cell therapy designed to recognize NKG2D ligands expressed on certain cancer cells, and NKX019, a CD19-targeted CAR NK cell therapy being developed for B-cell malignancies. The company has evaluated these programs in clinical studies involving conditions such as acute myeloid leukemia, myelodysplastic syndromes and B-cell cancers.

Founded in 2015 and headquartered in San Francisco, California, Nkarta focuses primarily on research and clinical development rather than commercialized products. Its activities are centered on advancing its cell therapy pipeline through clinical testing and regulatory development. The company’s therapies are investigational and have not been approved for commercial use.

Key Stats

• Today's Range: $2.79 to $2.89
• 50-Day Range: $2.09 to $3.23
• 52-Week Range: $1.70 to $3.72
• Volume: 609,733 shs
• Average Volume: 569,446 shs
• Market Capitalization: $202.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.20
• Consensus Rating: Moderate Buy

Nkarta Stock Analysis - MarketRank™

Nkarta scored higher than 53% of companies evaluated by MarketBeat, and ranked 433rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nkarta has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Nkarta has a consensus price target of $11.20, representing about 295.8% upside from its current price of $2.83.

Amount of Analyst Coverage

Nkarta has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nkarta are expected to grow in the coming year, from ($1.60) to ($1.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nkarta is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nkarta is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nkarta has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.32% of the float of Nkarta has been sold short.

Short Interest Ratio / Days to Cover

Nkarta has a short interest ratio ("days to cover") of 6.92.

Change versus previous month

Short interest in Nkarta has recently decreased by 4.47%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nkarta does not currently pay a dividend.

Dividend Growth

Nkarta does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 4 people have searched for NKTX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nkarta insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.80% of the stock of Nkarta is held by insiders.

Percentage Held by Institutions

80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/20/2026
• Stifel 2026 Virtual Immunology and Inflammation Forum: 9/23/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NKTX
• CIK: 1787400
• Web: www.nkartatx.com
• Phone: 925-407-1049
• Fax: N/A
• Employees: 106
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Nkarta: $11.20
• High Price Target: $14.00
• Low Price Target: $9.00
• Potential Upside/Downside: +295.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$104.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -39.64%
• Return on Assets: -30.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.98
• Quick Ratio: 7.98

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.40 per share
• Price / Book: 0.64

Miscellaneous

• Outstanding Shares: 71,620,000
• Free Float: 64,606,000
• Market Cap: $202.68 million
• Optionable: Optionable
• Beta: 0.97